Nitroglycerin-transdermal - Stowic

Drug Profile

Nitroglycerin-transdermal - Stowic

Latest Information Update: 19 Nov 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Stowic Resources
  • Class
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Angina pectoris

Most Recent Events

  • 19 Nov 2003 No development reported - Phase-I/II for Angina pectoris in United Kingdom (Transdermal)
  • 18 Oct 2002 The assets of Stowic Resources have been acquired by United Pharmaceuticals
  • 21 Nov 2001 Investigation in Angina pectoris in United Kingdom (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top